Skip to main content
OpenTrials
Completed

NCT Number: NCT04018209

Aquagenic Pruritus in Myeloproliferative Neoplasms

Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms.

Prospective work based on the distribution of a dedicated questionnaire.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases Myeloproliferative Disorders Pathological Conditions, Signs and Symptoms Pruritus Signs and Symptoms Skin Diseases Skin Manifestations Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

05, Lyon, Auvergne Rhônes-alpes, France

Loading trial locations.

About this study

Patients with myeloproliferative neoplasms identified and followed in French Hospitals. Patients could be followed for polycythemia vera or essential thrombocythemia or primary myelofibrosis.

Distribution of the questionnaire to each patient with myeloproliferative neoplasm (treated or not) suffering from aquagenic pruritus.

Analyse of each characteristic of the aquagenic pruritus by a statistician and publication at the end.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with one of three non-chromosomal Philadelphia-positive myeloproliferative neoplasms: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).
  • Suffering (or having suffered) from aquagenic pruritus.
  • No age limit, but major
  • Patient having formulated his non-opposition

Exclusion criteria

  • Patients with MPN with non-aquagenic pruritus,
  • Patients with another hematologic disease and aquagenic pruritus
  • Patients unable to complete the questionnaire.
  • Patients with physical or mental disabilities to formulate non-opposition
  • Refusal of participation

Treatment and study plan

Primary outcomes

  1. Description of pruritus in patients with myeloproliferative neoplasms

    Time frame: at the time of questionnaire completion (Day 0)

    Intensity of pruritus (visual analogic scale)

Secondary outcomes

  1. Description of therapies used to treat pruritus

    Time frame: at the time of questionnaire completion (Day 0)

    Name of drugs used

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Acronym: PANAM

Important dates

Study start
2019
Primary completion
2020
Study completion
2021
First posted
Jul 12, 2019
Registry last updated
Nov 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.